News und Analysen
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
EQS-News: MediClin AG: MEDICLIN focusses on innovative outpatient concepts in rehabilitation
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
Bronson Behavioral Health Hospital Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Bronson Behavioral Health Hospital, located in Battle Creek, Michigan. A
EQS-News: Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Premier, Inc. to Divest Non-Healthcare GPO Operations for Approximately $800 Million in Cash
Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced that it has entered into a definitive agreement with OMNIA
LivaNova to Announce Second-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A P
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “Capital Increase”) for
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today
Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference
Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf
New Study Shows That 84% of People With Diabetes Struggle With Mental Health1
As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc.
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity